HDAC inhibitors: Clinical update and mechanism-based potential
Top Cited Papers
- 7 April 2007
- journal article
- editorial
- Published by Elsevier
- Vol. 74 (5) , 659-671
- https://doi.org/10.1016/j.bcp.2007.04.007
Abstract
No abstract availableKeywords
This publication has 69 references indexed in Scilit:
- Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemiasBlood, 2006
- Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)Blood, 2006
- Anticancer activities of histone deacetylase inhibitorsNature Reviews Drug Discovery, 2006
- Restoration of Tamoxifen Sensitivity in Estrogen Receptor–Negative Breast Cancer Cells: Tamoxifen-Bound Reactivated ER Recruits Distinctive Corepressor ComplexesCancer Research, 2006
- Cardiac Studies in Patients Treated with Depsipeptide, FK228, in a Phase II Trial for T-Cell LymphomaClinical Cancer Research, 2006
- Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancerNature Reviews Cancer, 2006
- CLINICAL DEVELOPMENT OF HISTONE DEACETYLASE INHIBITORS AS ANTICANCER AGENTSAnnual Review of Pharmacology and Toxicology, 2005
- Reading signals on the nucleosome with a new nomenclature for modified histonesNature Structural & Molecular Biology, 2005
- Expression and functional characterization of recombinant human HDAC1 and HDAC3Life Sciences, 2004
- The language of covalent histone modificationsNature, 2000